Published in J Virol on July 01, 1999
Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev (2002) 3.27
Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol (2003) 2.98
Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol (2004) 2.47
Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol (2006) 2.33
Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol (2000) 1.70
Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors. J Clin Microbiol (2002) 1.66
Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev (2008) 1.26
Hydrophobic sliding: a possible mechanism for drug resistance in human immunodeficiency virus type 1 protease. Structure (2007) 1.20
The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors. AIDS Rev (2000) 1.15
Viral evolution in response to the broad-based retroviral protease inhibitor TL-3. J Virol (2001) 1.03
Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother (2003) 1.02
A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies. HIV Seq Compend (2001) 0.98
New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors. Curr Opin HIV AIDS (2008) 0.96
Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection. Drug Discov Today (2010) 0.96
Variant human immunodeficiency virus type 1 proteases and response to combination therapy including a protease inhibitor. Antimicrob Agents Chemother (2001) 0.90
Design of HIV-1-PR inhibitors that do not create resistance: blocking the folding of single monomers. Protein Sci (2005) 0.88
Molecular dynamics simulations of 14 HIV protease mutants in complexes with indinavir. J Mol Model (2004) 0.88
Insight into the folding inhibition of the HIV-1 protease by a small peptide. Biophys J (2007) 0.87
Protease polymorphisms in HIV-1 subtype CRF01_AE represent selection by antiretroviral therapy and host immune pressure. AIDS (2010) 0.83
Cooperative effects of drug-resistance mutations in the flap region of HIV-1 protease. ACS Chem Biol (2012) 0.82
Conservation of functional domains and limited heterogeneity of HIV-1 reverse transcriptase gene following vertical transmission. Retrovirology (2005) 0.82
Multiple routes and milestones in the folding of HIV-1 protease monomer. PLoS One (2010) 0.79
Use of the l1 norm for selection of sparse parameter sets that accurately predict drug response phenotype from viral genetic sequences. AMIA Annu Symp Proc (2005) 0.75
Natural polymorphisms and unusual mutations in HIV-1 protease with potential antiretroviral resistance: a bioinformatic analysis. BMC Bioinformatics (2014) 0.75
HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science (1995) 18.40
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med (1996) 6.14
Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med (1996) 5.35
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol (1996) 4.45
Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol (1997) 3.64
Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database. Nucleic Acids Res (1999) 3.44
The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med (1996) 3.35
Maintaining the integrity of human immunodeficiency virus sequence databases. J Virol (1996) 2.68
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother (1998) 2.67
Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS (1996) 2.14
Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe. AIDS Res Hum Retroviruses (1999) 1.18
HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy. AIDS (1998) 1.13
Point mutant frequencies in the pol gene of human immunodeficiency virus type 1 are two- to threefold lower than those of env. AIDS Res Hum Retroviruses (1996) 1.03
Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 0.90
Construction and expression of recombinant plasmids encoding type 1 or D-mannose-resistant pili from a urinary tract infection Escherichia coli isolate. Infect Immun (1981) 14.05
A computer algorithm for testing potential prokaryotic terminators. Nucleic Acids Res (1984) 4.73
Distribution patterns of HP1, a heterochromatin-associated nonhistone chromosomal protein of Drosophila. Eur J Cell Biol (1989) 4.52
Optimal spliced alignment of homologous cDNA to a genomic DNA template. Bioinformatics (2000) 3.14
Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc Natl Acad Sci U S A (1999) 2.44
HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med (1999) 2.36
Statistical methods and insights for protein and DNA sequences. Annu Rev Biophys Biophys Chem (1991) 2.32
Chance and statistical significance in protein and DNA sequence analysis. Science (1992) 2.25
Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem (1997) 2.04
Identification of significant sequence patterns in proteins. Methods Enzymol (1990) 1.99
Molecular cloning of a human homologue of Drosophila heterochromatin protein HP1 using anti-centromere autoantibodies with anti-chromo specificity. J Cell Sci (1993) 1.90
Charge configurations in oncogene products and transforming proteins. Oncogene (1990) 1.85
A method to identify distinctive charge configurations in protein sequences, with application to human herpesvirus polypeptides. J Mol Biol (1989) 1.75
Bacterial classifications derived from recA protein sequence comparisons. J Bacteriol (1995) 1.66
Significant similarity and dissimilarity in homologous proteins. Mol Biol Evol (1992) 1.57
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. J Med Chem (1999) 1.55
Evaluation of corn hybrids expressing Cry1F, cry1A.105, Cry2Ab2, Cry34Ab1/Cry35Ab1, and Cry3Bb1 against southern United States insect pests. J Econ Entomol (2012) 1.54
Coexpression of class I major histocompatibility antigen and viral RNA in central nervous system of mice infected with Theiler's virus: a model for multiple sclerosis. Mayo Clin Proc (1992) 1.53
Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection. Pediatr Infect Dis J (2001) 1.51
Multi-query sequence BLAST output examination with MuSeqBox. Bioinformatics (2001) 1.51
Patchiness and correlations in DNA sequences. Science (1993) 1.47
Gene discovery using the maize genome database ZmDB. Nucleic Acids Res (2000) 1.41
Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob Agents Chemother (2001) 1.37
Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. Genomics (2000) 1.33
Aspects of X-ray diffraction on single spider fibers. Int J Biol Macromol (1999) 1.31
Multiple isoforms of GAGA factor, a critical component of chromatin structure. Nucleic Acids Res (1997) 1.30
Too many leucine zippers? Nature (1989) 1.27
Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis (1994) 1.27
Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob Agents Chemother (2005) 1.25
Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements. J Med Chem (1998) 1.24
Chief residency in PM&R. A balance of education and administration. Am J Phys Med Rehabil (1996) 1.23
Outbreak of mumps among young adults--Vancouver, British Columbia. Can Commun Dis Rep (1997) 1.22
Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease. J Med Chem (1996) 1.19
Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe. AIDS Res Hum Retroviruses (1999) 1.18
Temperature sensitive simian virus 40 large T antigen immortalization of murine odontoblast cell cultures: establishment of clonal odontoblast cell line. Connect Tissue Res (1995) 1.16
Role of natural killer cells as immune effectors in encephalitis and demyelination induced by Theiler's virus. J Immunol (1989) 1.16
Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS (1999) 1.15
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies. J Med Chem (1998) 1.14
Inhibition of human rhinovirus-induced cytokine production by AG7088, a human rhinovirus 3C protease inhibitor. Antimicrob Agents Chemother (2000) 1.13
Molecular characterization of a mutable pigmentation phenotype and isolation of the first active transposable element from Sorghum bicolor. Proc Natl Acad Sci U S A (1999) 1.13
Is the central dogma of flow cytometry true: that fluorescence intensity is proportional to cellular dye content? Cytometry (1982) 1.13
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies. J Med Chem (1998) 1.12
Gene structure prediction by spliced alignment of genomic DNA with protein sequences: increased accuracy by differential splice site scoring. J Mol Biol (2000) 1.05
Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333. J Infect Dis (2000) 1.04
U-richness is a defining feature of plant introns and may function as an intron recognition signal in maize. Plant Mol Biol (1998) 1.04
A computer-aided design mammography screening system for detection and classification of microcalcifications. Int J Med Inform (2000) 1.01
Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res (1993) 1.01
The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691). Clin Pharmacol Ther (2011) 1.01
Renal response to a saline load in well-compensated alcoholic cirrhosis. Hepatology (1994) 1.00
Test of the combinatorial model of intron recognition in a native maize gene. Plant Mol Biol (1999) 1.00
Eosinophilic granuloma. A different behaviour in children than in adults. J Bone Joint Surg Br (2002) 1.00
Age dependence of cerebrovascular response mechanisms in domestic pigs. Am J Physiol (1996) 0.99
Charge configurations in viral proteins. Proc Natl Acad Sci U S A (1988) 0.99
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics. J Med Chem (1999) 0.98
Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease. Antimicrob Agents Chemother (1995) 0.98
An actin-related protein in Drosophila colocalizes with heterochromatin protein 1 in pericentric heterochromatin. J Cell Sci (1997) 0.98
Therapeutic uses of recombinant complement protein inhibitors. Springer Semin Immunopathol (1994) 0.97
Abrogation of resistance to Theiler's virus-induced demyelination in C57BL mice by total body irradiation. J Neuroimmunol (1990) 0.96
Analyzing heterochromatin formation using chromosome 4 of Drosophila melanogaster. Cold Spring Harb Symp Quant Biol (2004) 0.95
How do long-term development and periodical changes of river-floodplain systems affect the fate of contaminants? Results from European rivers. Environ Pollut (2009) 0.95
Inhibition of Theiler's virus-induced demyelination in vivo by tumor necrosis factor alpha. Int Immunol (1990) 0.94
Epiphyseal injuries. Pediatr Clin North Am (1974) 0.94
In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother (2007) 0.94
48-hour sleep-wake cycles in manic-depressive illness: naturalistic observations and sleep deprivation experiments. Arch Gen Psychiatry (1982) 0.93
Latino physician supply in California: sources, locations, and projections. Acad Med (2000) 0.92
Role of T cell receptor V beta genes in Theiler's virus-induced demyelination of mice. J Immunol (1992) 0.92
Effect of altered lymphocyte function on immunologic disorders in NZB/NZW mice. III. Acceleration of disease by thymosin. Arthritis Rheum (1978) 0.90
Logitlinear models for the prediction of splice sites in plant pre-mRNA sequences. Nucleic Acids Res (1996) 0.88
Molecular characterization of a nondemyelinating variant of Daniel's strain of Theiler's virus isolated from a persistently infected glioma cell line. J Virol (1998) 0.88
Effects of caffeine, practice, and mode of presentation on Stroop task performance. Pharmacol Biochem Behav (1996) 0.87
Timing of the expression of enamel gene products during mouse tooth development. Int J Dev Biol (1997) 0.87
Identification of the site in the substance P (NK-1) receptor for modulation of peptide binding by sulfhydryl reagents. J Biol Chem (1996) 0.86
Indomethacin-induced renal dysfunction in patients with well-compensated cirrhosis. Gastroenterology (1993) 0.86
Intervening sequences exhibit distinct vocabulary. J Biomol Struct Dyn (1986) 0.86
Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor. Antimicrob Agents Chemother (1996) 0.86
Biochemical and biophysical characteristics of Rio Bravo virus (Flaviviridae). J Gen Virol (1988) 0.86
Solid-phase synthesis of irreversible human rhinovirus 3C protease inhibitors. Part 1: Optimization of tripeptides incorporating N-terminal amides. Bioorg Med Chem (1999) 0.85
Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine. J Infect Dis (2000) 0.85
An outbreak of mumps among young adults in Vancouver, British Columbia, associated with 'rave' parties. Can J Public Health (1999) 0.84
Control of responding by the location of sound: role of binaural cues. J Exp Anal Behav (1985) 0.84
Isocitrate dehydrogenase from bovine heart: primary structure of subunit 3/4. Biochem J (1995) 0.84
Genome structure described by formal languages. Nucleic Acids Res (1984) 0.84
Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitors. Bioorg Med Chem Lett (2000) 0.84
Direct bone resorbing activity of murine myeloma cells. Cancer Lett (1983) 0.83
A combinatorial role for exon, intron and splice site sequences in splicing in maize. Plant J (1997) 0.83
Personal history, training, and worksite as predictors of back pain of nurses. Am J Ind Med (1994) 0.83
Kinetics of complementary RNA-RNA interaction involved in plasmid ColE1 copy number control. J Mol Biol (1989) 0.82
Reproducibility of LSI HER-2/neu SpectrumOrange and CEP 17 SpectrumGreen Dual Color deoxyribonucleic acid probe kit. For enumeration of gene amplification in paraffin-embedded specimens: a multicenter clinical validation study. Ann Clin Lab Sci (1998) 0.82
A novel adenoviral vector expressing human Fas/CD95/APO-1 enhances p53-mediated apoptosis. Cell Death Differ (1999) 0.81
Dilator prostanoid-induced cyclic AMP formation and release by cerebral microvascular smooth muscle cells: inhibition by indomethacin. J Pharmacol Exp Ther (1995) 0.81
A recombinant adenovirus expressing wild type p53 induces apoptosis in drug-resistant human breast cancer cells: a gene therapy approach for drug-resistant cancers. Cancer Gene Ther (1998) 0.80
Expression of human HLA-B27 transgene alters susceptibility to murine Theiler's virus-induced demyelination. J Immunol (1991) 0.80
GeneGenerator--a flexible algorithm for gene prediction and its application to maize sequences. Bioinformatics (1998) 0.80
A comparative analysis of distinctive features of yeast protein sequences. Yeast (1993) 0.80
Estrogen and prothrombin synthesis: effect of estrogen on absorption of vitamin K1. Am J Physiol (1977) 0.78
Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir. Antivir Ther (2001) 0.78
The development of resistance of HIV-1 to zalcitabine. AIDS (1997) 0.78
Spliceosomal proteins in plants. Curr Top Microbiol Immunol (2008) 0.78
A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Cancer Res (1995) 0.77
Dose-dependent effects of oral misoprostol on renal function in alcoholic cirrhosis. Gastroenterology (1994) 0.77